Disease Focus Areas
We Focus on Vaccine-preventable Diseases
We focus on vaccines to prevent diseases that cause devastating health effects and death in low- and middle-income countries (LMICs).

Cholera
In 2024, Sabin partnered with the Kenya Medical Research Institute (KEMRI) to optimize the use of the oral cholera vaccine.

Dengue
In recent decades, the incidence of dengue has grown dramatically around the world, with the World Health Organization reporting just over 500,000 global cases in 2000 and more than 5 million in 2019.

Human Papilloma Virus
A Sabin-hosted public-private movement to prevent Human Papilloma Virus (HPV) infection and eliminate cervical cancer as a public health concern.

Marburg
We’re developing a vaccine for Marburg, a virus similar to Ebola, and one of the world’s deadliest infectious diseases.

Malaria
In 2022, there were an estimated 249 million malaria cases worldwide, with the majority occurring in the tropical regions, making this disease a priority area for Sabin.

Sudan ebolavirus
Since 2019, we’ve been developing a vaccine for Sudan ebolavirus to prevent this deadly virus.

Typhoid
We work to ensure that countries where typhoid is common have the data they need to make strategic decisions about introducing typhoid vaccines. We also partner with scientists and health workers to advance a holistic approach to preventing disease.

Measles
Measles continues to be a rising threat with concerns surrounding global vaccine hesitancy. In 2023 the WHO released estimates that showed a 20% increase in measles cases over 2022 numbers.
Our Impact
Sabin works to ensure everyone can access life-saving vaccines when they need them. We advance innovative research and increase vaccine acceptance and demand.
Our Programs
Sabin strengthens communities by advancing global immunization and developing innovative vaccines.

We make vaccines more accessible, enable innovation and expand immunization across the globe.